Its usually administered via subcutaneous injection and has been shown to be effective in lowering HbA1c levels (a measure of long-term blood glucose control) and reducing body weight in clinical trials
One of the mechanisms that are currently investigated is the Wnt signalling pathway
Some people get stomach issues like cramping, bloating, and occasional loose stools
Markets are now watching pricing, insurance coverage, and patient adoption as the next determinants of how disruptive this shift from injections to pills could be
When you lose weight, especially quickly, the skin may not have enough time or structural support to contract back to its smaller size
In obesity, the next strategic question is not: How much weight loss can your drug deliver? It is: Which patient segment can your asset credibly own? That is where the real market will be created To view or add a comment, sign in The real value of innovation in obesity medicine isnt achieving greater weight reduction anymore
